Similar Papers

Paper Title
Journal
Date
Author
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?
U.A Matulonis ... B.J Monk
Annals of Oncology | VOL. 28
U.A Matulonis, et. al.U.A Matulonis ... B.J Monk
01 Mar 2017
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness
A Tutt
Annals of Oncology | VOL. 29
A TuttA Tutt
01 Jan 2018
Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients
D F Wang ... G N Zhang
Zhonghua fu chan ke za zhi | VOL. 57
D F Wang, et. al.D F Wang ... G N Zhang
25 Sep 2022
PARP inhibitors for targeted treatment in ovarian cancer
Don S Dizon
The Lancet | VOL. 390
Don S DizonDon S Dizon
12 Sep 2017
View more papers

More From: International Journal of Gynecologic Cancer

Paper Title
Journal
Date
Author
Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study
Premal H Thaker ... Amanda K Golembesky
International Journal of Gynecologic Cancer | VOL. 34
Premal H Thaker, et. al.Premal H Thaker ... Amanda K Golembesky
01 Dec 2024
Correspondence on ‘Cardiophrenic and costophrenic lymphadenectomy in advanced ovarian cancer by prediaphragmatic subxiphoid approach: PS technique’ by Stanciu
Cagatay Taskiran ... Dogan Vatansever
International Journal of Gynecologic Cancer | VOL. 34
Cagatay Taskiran, et. al.Cagatay Taskiran ... Dogan Vatansever
01 Dec 2024
Laparoscopic transperitoneal resection of bulky aortocaval and infrarenal metastatic lymph nodes in a patient with locally advanced cervical carcinoma
Nasuh Utku Dogan ... Selin Er
International Journal of Gynecologic Cancer | VOL. 34
Nasuh Utku Dogan, et. al.Nasuh Utku Dogan ... Selin Er
01 Dec 2024
Correction: Extra-cranial meningioma associated with relapse of immature ovarian teratoma
-
International Journal of Gynecologic Cancer | VOL. 34
--
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.